window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Drug Delivery

  • Central Nervous System,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome

    Emalex Biosciences has secured a US patent for an orally [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Bio-Sourcing and Tiny Cargo partner to develop oral monoclonal antibodies using milk exosomes

    Bio-Sourcing and Tiny Cargo will develop oral monoclonal antibody therapies [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Delivery & Formulation,Drug Discovery & Development,Therapeutic Areas

    Nanexa targets next-generation ‘fat jab’ with monthly semaglutide delivery platform

    Sweden-based Nanexa has reported preclinical data for a long-acting semaglutide [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bio‑Sourcing and Zerion Pharma collaborate on first oral HER2 monoclonal antibody

    Bio‑Sourcing and Zerion Pharma have joined forces to develop the [...]

    May 5, 2026
  • Drug Delivery & Formulation,Manufacturing & Supply Chain,Opinion & Events

    Pharmapack 2026 to return to Paris with focus on GLP-1 therapies and sustainable packaging

    Pharmapack will return to Paris in January 2026, with this [...]

    May 5, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Nanexa and Moderna sign licence and option agreement for Pharmashell drug delivery development

    Nanexa has entered into a licence and option agreement with [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Pharmaceuticals and therapeutics

    CPHI Frankfurt Pharma Awards 2025 finalists unveiled, spotlighting innovation, sustainability and industry leadership

    From synthetic biology to patient access, AI-powered formulation to sustainable [...]

    May 5, 2026
  • Drug Delivery & Formulation,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Nanexa secures Japanese patent for PharmaShell technology

    Nanexa has received approval for a Japanese patent covering a [...]

    May 5, 2026
  • Drug Delivery & Formulation,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    SGD Pharma to acquire Alphial to expand tubular glass and vial manufacturing in Europe

    SGD Pharma has signed an agreement with Italian private equity [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Drug Delivery & Formulation,Drug Discovery & Development,Manufacturing & Supply Chain

    LNP pioneer Pieter Cullis joins Hongene’s scientific advisory board

    Hongene has appointed leading lipid nanoparticle (LNP) researcher Pieter Cullis [...]

    May 5, 2026
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Grow Therapy study finds most patients report meaningful improvement in depression and anxiety symptoms
    Categories: Clinical & Regulatory, Digital & Data, Therapeutic Areas
  • EPIK Biosciences launches with ketamine pipeline targeting mental health, chronic pain and addiction
    Categories: Biotech & Pharma Business, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Incannex links PSX-001 psilocybin programme to White House push on psychedelic mental health treatments
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top